A principal active antimicrobial compound, 2-(3′,5′-dibromo-2′-methoxyphenoxy)-3,5-dibromophenol, was isolated from the methanol extract of Phyllospongia papyracea via bioassay-guided fractionation and isolation. The crude extract and the purified compound were assayed to determine the minimal inhibitory concentration and minimal bactericidal concentration (MBC) using the broth microdilution method. The purified compound was found to be highly active against Bacillus subtilis and Staphylococcus aureus at MIC=1 µg/mL, Campylobacter jejuni at MIC=2 µg/mL, Pseudomonas aeruginosa at MIC=4 µg/mL, and Streptococcus pneumoniae and Listeria monocytogenes at MIC = 8 µg/mL. The activity of this compound was found to be comparable with antibiotics commonly used to control these species of bacteria. The results establish 2-(3′,5′-dibromo-2′-methoxyphenoxy)-3,5-dibromophenol as a potential lead molecule for the development of antibacterial agents.
Bacterial antibiotic resistance is increasing at a staggering rate and poses a significant health threat worldwide [1] [2] [3] . Of particular concern are those organisms which have developed resistance to several classes of antibiotics. As bacterial resistance to traditional treatments increases, there is also growing interest in the evaluation of natural product repositories for compounds which possess antimicrobial activity. The screening of natural sources has been a key in the discovery of many classes of drugs. Reports estimate that 60% of commercially available anti-infective agents are of natural origin [2, 4] . Marine sources have been found to be an invaluable source of bioactive compounds. Marine sponges have developed chemical defenses to protect against the colonization of pathogenic bacteria [5] . For this reason, the antimicrobial activity of marine sponges has been extensively studied in an attempt to harness the sponges' natural potency [6] . The discovery of antimicrobial properties of sponges has the potential to be applied in a wide variety of settings including pharmaceuticals, agriculture, and food preservation. Furthermore, natural antimicrobials may eventually replace traditional approaches of controlling pathogens [7] .
Phyllospongia papyracea is a marine sponge of the Dictyoceratida order. Two types of molecular structures have been recorded for Phyllospongia, scalarane sesterpenes and polybrominated biphenyl ethers [8] . While much research has been conducted on the former, the bioactivity of the latter is less well known. Bromophenolic compounds are present in high concentrations in marine sponges and have shown antibacterial [9] , antifungal [10] , and antiinflammatory activities , as well as being cytotoxic [2, 9, 11] . In this experiment, we investigated the antimicrobial activity of a polybrominated biphenyl ether, 2-(3′,5′-dibromo-2′-methoxyphenoxy)-3,5-dibromophenol, using a broad spectrum of bacterial species to develop a thorough antimicrobial profile. Species included in the investigation are those which cause a high incidence of infection, as well as those which have been reported to be developing multi-drug resistance. To the best of our knowledge, this is the first report of the activity of this compound on these bacterial species. The crude methanol extract of P. papyracea showed broadspectral inhibition when assayed against pathogenic bacteria such as Bacillus subtilis, Campylobacter jejuni, Listeria Table 1 ). The extract was partitioned by liquid-liquid extraction using n-hexane, ethyl acetate, n-butanol, and sterile distilled water; the n-hexane and ethyl acetate fractions exhibited antimicrobial activity. These two fractions were combined and subjected to fractionation via open column chromatography and led to one purified component with antimicrobial activity. The active compound, appearing as a white powder, was identified using NMR and mass spectra.
In the high-resolution electrospray ionization mass spectrum (HRESIMS), groups of quasimolecular [M-H]ion peaks were observed at m/z 526.7120 (15) The NMR spectral data were in agreement with those previously reported for 2-(3′,5′dibromo-2′-methoxyphenoxy)-3,5-dibromophenol ( Figure 1 ) [11] . This compound was previously found to possess antimicrobial activity by inhibiting S. aureus and Trichophyton mentographytes (MIC 100 0.15, 1.56 µg/mL, respectively) [9] . Furthermore, it has been found to possess antimicroalgal activity against Skeletonema costatum and Brachiomonas submaria at 0.5 ppm [11] . A compound with a structure later revised to match this compound was found to inhibit hypoxia-induced HIF-1 activation (IC 50 =4.3µM), but also reduced the viability of T47D and MDA-MD-231 breast tumor cells [3] . The isolated compound, 2-(3′,5′-dibromo-2′-methoxyphenoxy)-3,5dibromophenol, had a lower activity than that of the crude P. papyracea extract based on MIC values (Table 1) . There are two possible reasons for this. The first is that the compound, when isolated, is relatively unstable. A further explanation could be that the compound works synergistically with another or several other compounds to exert its effect.
The specific species of bacteria investigated in this study are those which have high incidence of human infection, those attributed with causing food-borne illnesses, and those which are currently not well controlled due to the increasing antibiotic resistance.
Fluoroquinolones such as ciprofloxain, levofloxacin, and moxifloxacin are often prescribed for treatment of S. pneumoniae infection [12] . However, increasing resistance of S. pneumoniae to fluoroquinolones has been noted [13] . As shown in Tables 1 and 2, the tetrabrominated diphenyl ether isolated from P. papyracea exhibited antimicrobial activity equivalent to the fluoroquinolones (MIC = 0.25 µg/mL). Considering the increasing resistance of S. pneumoniae to the fluoroquinolones, this compound has potential application in the treatment of S. pneumoniae infection.
We further found that the isolated compound possessed inhibitory activity on the Gram-positive, spore-forming pathogen C. difficile. C. difficile infection (CDI) is the most common cause of antibioticassociated diarrhea in hospitals and health care facilities [14] . The clinical C. difficile strain obtained in this study is resistant to the fluoroquinolone ciprofloxacin, yet is highly susceptible to 2-(3′,5′dibromo-2′-methoxyphenoxy)-3,5-dibromophenol. This compound may offer a potential application in treatment of CDI, as the fluoroquinolone resistant strain NAP1/BI/027 is responsible for an increasing number of outbreaks in hospitals, and current antibiotic therapy has numerous limitations. The results (Tables 1 and 2) indicate that this compound might serve either as a drug candidate or a lead compound for future antibiotic development for the fluoroquinolone resistant strain of C. difficile.
A third bacterial species that was found to be greatly inhibited by the isolated compound from P. papyracea was C. jejuni. This species was included in this investigation as it is currently a leading cause of enteric bacterial infection worldwide [15] . C. jejuni has become increasingly resistant to antimicrobial agents such as fluoroquinolones, limiting the effectiveness of therapeutic options. Transmission of antimicrobial-resistant C. jejuni from food animals to humans raises public health concern as resistance rises in C. jejuni isolates of animal origin [16] . In the present study, we demonstrated that the activity of 2-(3′,5′-dibromo-2′-methoxyphenoxy)-3,5-dibromophenol against C. jejuni (MIC = 0.5 µg/mL) is comparable with the MIC levels obtained from antibiotic assay of currently used pharmaceutical fluoroquinolones (MIC = 0.25 µg/mL). This compound was equally effective as erythromycin against C. jejuni, which demonstrated a MIC of 0.5 µg/mL (Tables  1 and 2 ). With such strong inhibitory activity, 2-(3′,5′-dibromo-2′methoxyphenoxy)-3,5-dibromophenol may be an alternative candidate for future antimicrobial development.
The mechanism through which this compound exerts its activity is unknown, but we have demonstrated that it can exert activity on some species of Gram-positive and Gram-negative bacteria. Of great importance is that this compound exhibited selectivity of inhibition, displaying MIC values greater than 16 µg/mL for all other bacterial strains tested.
In summary, in this study we isolated and identified a principal active compound, 2-(3′,5′-dibromo-2′-methoxyphenoxy)-3,5dibromophenol from P. papyracea, which expresses specific inhibitory activity on S. pneumoniae, C. difficile, and C. jejuni. Future research should focus on elucidating the mechanism by which this compound exerts its antimicrobial activity.
Experimental
Materials and methods: NMR spectra ( 1 H, 13 C, DEPT) were recorded on a Varian Mercury 400 MHz instrument. Chemical shifts are given in δ values, and J values in Hz. Mass spectra were obtained on a QSTAR XL MS/MS system.
Sample preparation:
The crude methanol extract from Phyllospongia papyracea (3.0 g) obtained from the natural products repository of the National Cancer Institute (NCI) of the National Institutes of Health (NIH) was partitioned by liquid-liquid extraction using n-hexane, ethyl acetate, n-butanol, and sterile distilled water. Bioactivity assays revealed that the n-hexane and ethyl acetate fractions exhibited antimicrobial activity. These two fractions were combined (2.8 g) and subjected to fractionation via open column chromatography. The chromatography was carried out on 100 g of silica gel (40-60 μm, Acros, NJ) in a glass column (457×40 mm) and eluted with n-hexane, acetone, and methanol to yield a total of 15 fractions. Fractions were monitored on TLC Silica Gel 60 F254 (EMD, Gibbstown, NJ) and visualized under UV (254 nm and 365 nm) and by spraying with 10% H 2 SO 4 (in EtOH). Fractions 3 and 4 were identified as active and were further purified by high performance liquid chromatography (HPLC) on a reverse phase C18 column (150 x 4.6 mm) using a Hitachi DAD L-2455 detector to obtain the pure active compound (303.8 mg). The UV-VIS spectrum was recorded in methanol/H 2 O using a Hitachi DAD L-2455. 
Bacteria and media:

